Advances in Airway-on-Chip Repair Models: Mechanistic Insights and Clinical Implications

Abstract

Airway-on-chip repair models represent a transformative frontier in respiratory research, enabling precise simulation of human airway physiology, disease pathology, and therapeutic response. By combining microfluidics, 3D cell culture, and tissue engineering, these platforms address critical gaps in traditional preclinical models, offering unprecedented fidelity for studying airway injury and regeneration. This review synthesizes current evidence, highlights recent advances, and evaluates the translational potential of airway-on-chip technologies for clinicians and researchers.

Introduction

Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and acute lung injury impose a significant global health burden. The airway epithelium is central to these pathologies, serving as both a barrier and a regulator of immune responses. Traditional in vitro and animal models are limited in their ability to recapitulate the complex microenvironment of the human airway. Airway-on-chip repair models have emerged as innovative platforms, providing dynamic, physiologically relevant systems for investigating airway injury, repair, and regeneration. This review offers an in-depth analysis of airway-on-chip models, focusing on their development, mechanistic insights, clinical relevance, and future directions for translational medicine.

Epidemiology / Disease Burden

Respiratory diseases collectively account for millions of deaths annually and a substantial proportion of global morbidity. According to the World Health Organization, chronic respiratory diseases affect over 500 million people worldwide. Acute airway injuries, such as those due to infections, environmental exposures, or medical interventions (e.g., intubation), further exacerbate healthcare challenges. The need for effective repair strategies is underscored by the high prevalence of airway remodeling and dysfunction in chronic conditions. Airway-on-chip models provide a critical tool for unraveling disease mechanisms and testing reparative interventions in a setting that closely mimics human pathophysiology.

Pathophysiology

The integrity of the airway epithelium is a key determinant of respiratory health. Injury to this barrier via infection, inflammation, toxins, or mechanical stress triggers a cascade of repair mechanisms involving basal cell proliferation, differentiation, and migration. Dysregulation of these processes can lead to chronic inflammation, aberrant remodeling, and impaired gas exchange. Airway-on-chip models utilize human-derived epithelial, stromal, and sometimes immune cells within microengineered environments, allowing detailed study of these pathophysiological processes under controlled conditions. Fluid flow, cyclic stretch, and air-liquid interface can be precisely modulated, offering insights into the cellular and molecular mechanisms driving airway repair and regeneration.

Risk Factors

Multiple risk factors contribute to airway injury and impaired repair, including tobacco smoke, air pollution, occupational exposures, genetic predispositions, and comorbid conditions such as diabetes or immunodeficiency. Infections (viral, bacterial, fungal) frequently precipitate acute epithelial damage. Airway-on-chip models allow researchers to introduce specific risk factors such as particulate matter, pathogens, or cytokines and observe their impact on epithelial integrity, ciliary function, and repair dynamics. This mechanistic understanding is critical for identifying high-risk patient populations and tailoring preventive or therapeutic interventions.

Clinical Features

Clinical manifestations of airway injury and defective repair span from acute symptoms cough, wheezing, dyspnea to chronic sequelae such as airway hyperresponsiveness, fibrosis, and recurrent infections. Traditional assessment relies on spirometry, imaging, and histopathology, but these modalities offer limited mechanistic insight. Airway-on-chip models bridge this gap by facilitating real-time analysis of ciliary beating, mucus secretion, barrier function, and inflammatory mediator release. Such patient-specific and disease-relevant features can be recapitulated in vitro, enabling the study of genotype-phenotype correlations and personalized medicine approaches.

Diagnosis

Diagnosis of airway injury and repair abnormalities traditionally involves clinical evaluation, pulmonary function testing, and biopsy. However, these approaches have inherent limitations, including invasiveness and lack of dynamic resolution. Airway-on-chip technologies offer potential for ex vivo diagnostic applications, such as evaluating epithelial responses to allergens, drugs, or environmental toxins using patient-derived cells. Integration with biosensors and omics technologies enhances the ability to detect subtle changes in cellular health, gene expression, or secretome profiles, paving the way for precision diagnostics and early intervention strategies.

Treatment & Management

Current management of airway injury and defective repair centers on addressing underlying causes, minimizing further damage, and supporting tissue regeneration. Interventions range from pharmacologic agents (e.g., corticosteroids, bronchodilators, mucolytics) to supportive care and, in severe cases, surgical interventions. Airway-on-chip models facilitate the preclinical screening of novel therapeutics including small molecules, biologics, and gene therapies under physiologically relevant conditions. These platforms also enable exploration of cell-based therapies, such as stem cell transplantation or exosome delivery, for promoting epithelial repair and functional recovery.

Recent Advances / Emerging Therapies

Recent years have seen remarkable progress in airway-on-chip design and application. Innovations include multi-layered microfluidic devices that incorporate vascular, immune, and mesenchymal components, as well as advanced biomaterials that mimic the extracellular matrix. CRISPR-based gene editing, real-time imaging, and high-throughput drug screening have been successfully integrated into these systems. Notable studies have demonstrated the utility of airway-on-chip models for evaluating antiviral agents against SARS-CoV-2, elucidating host-pathogen interactions, and modeling rare genetic disorders such as cystic fibrosis. Such advances hold promise for accelerating the translation of benchside discoveries to bedside therapies.

Guideline Recommendations

While airway-on-chip models are not yet integrated into standard clinical guidelines, leading respiratory societies and translational research consortia emphasize the importance of advanced preclinical models for bridging gaps between animal studies and human trials. Incorporating airway-on-chip platforms into drug development pipelines is advocated to improve prediction of human efficacy and safety. Ongoing efforts aim to establish standardized protocols, quality control measures, and regulatory frameworks to facilitate clinical adoption and harmonize research outputs across centers.

Conclusion

Airway-on-chip repair models represent a paradigm shift in respiratory research and regenerative medicine. By faithfully recapitulating human airway physiology and pathobiology, these platforms offer unique opportunities for mechanistic discovery, therapeutic screening, and personalized medicine. Continued innovation and multidisciplinary collaboration are essential to realize their full clinical potential and to integrate these transformative tools into the future of respiratory care.